Experiment 68659
Worktypes
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Empty organism |
| Citation | BHARGAVA,P: MARSHALL,JL: DAHUT,W: RIZVI,N: TROCKY,N: WILLIAMS,JI: HAIT,H: SONG,S: HOLROYD,KJ: HAWKINS,MJ:. (2001). A PHASE I AND PHARMACOKINETIC STUDY OF SQUALAMINE, A NOVEL ANTIANGIOGENIC AGENT, IN PATIENTS WITH ADVANCED CANCERS.. 7(12) |
| Amount utilized | |
| Compound isolated | |
| Disease | A PHASE I AND PHARMACOKINETIC STUDY OF SQUALAMINE, A NOVEL ANTIANGIOGENIC AGENT IN ADVANCED CANCER PATIENTS, SHOWED THE BEST TOLERATED DOSE RATE AT 120H CONTINOUS INFUSION (1V) 192MG PER M-2 PER DAY BUT PATIENTS WITHOUT PRIOR EXPOSURE TO SQUALAMINE APPEARED TO TOLERATE A DOSE RATE OF 384,H/M-2/DAY WITHOUT DLT. |
| Dose amount | 192.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Gender | GIVEN TO BOTH SEXES |